AL SJR60

Encourages the Alabama Medicaid Agency to evaluate potential cost savings from covering GLP-1 weight management medications (such as Ozempic and Wegovy) for Medicaid members

Approximately 110,000 adult and child Medicaid members in Alabama may qualify for GLP-1 medications based on current FDA labeling

Cites obesity's economic impact: $173 billion annually in U.S. medical expenditures, $7.2 billion negative impact on Alabama's GDP, and over $750 million annual impact on the state budget

Notes Alabama's obesity prevalence at 38.9% for adults and 15.6% for children enrolled in the WIC program

Requests the agency report findings to the Legislature prior to the 2027 Legislative Session, including analysis of new federal drug pricing models expected by Spring 2026